| SEGMENTED INFORMATION AND ECONOMIC DEPENDENCE |
20.SEGMENTED INFORMATION AND ECONOMIC DEPENDENCE At April 30, 2025, 2024 and 2023, the Company has one reportable segment, being antibody production and related services. The Company’s revenues are allocated to geographic regions for the year ended April 30, 2025, 2024 and 2023 as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years ended
April 30, |
|
Revenue by Region
(in thousands) |
|
2025
$ |
|
|
2024
$ |
|
|
2023
$ |
|
United States of America |
|
|
12,614 |
|
|
|
12,556 |
|
|
|
9,365 |
|
Europe |
|
|
10,178 |
|
|
|
10,867 |
|
|
|
9,450 |
|
Canada |
|
|
234 |
|
|
|
389 |
|
|
|
618 |
|
Australia |
|
|
896 |
|
|
|
482 |
|
|
|
630 |
|
Other |
|
|
598 |
|
|
|
224 |
|
|
|
602 |
|
|
|
|
24,520 |
|
|
|
24,518 |
|
|
|
20,665 |
|
The Company’s revenues are allocated according to revenue types for the year ended April 30, 2025, 2024 and 2023 as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years ended
April 30, |
|
Revenue Allocation
(in thousands) |
|
2025
$ |
|
|
2024
$ |
|
|
2023
$ |
|
Project revenue |
|
|
22,175 |
|
|
|
22,235 |
|
|
|
18,677 |
|
Product sales revenue |
|
|
2,107 |
|
|
|
2,035 |
|
|
|
1,747 |
|
Cryostorage revenue |
|
|
238 |
|
|
|
248 |
|
|
|
241 |
|
|
|
|
24,520 |
|
|
|
24,518 |
|
|
|
20,665 |
|
As of April 30, 2025, all deferred revenue is expected to be recognized over the next twelve months. The Company’s non-current assets are allocated to geographic regions as of April 30, 2025, 2024 and 2023 as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Current Assets
(in thousands) |
|
2025
$ |
|
|
2024
$ |
|
|
2023
$ |
|
North America - Corporate |
|
|
80 |
|
|
|
80 |
|
|
|
89 |
|
North America |
|
|
4,167 |
|
|
|
4,138 |
|
|
|
1,025 |
|
Belgium |
|
|
268 |
|
|
|
22,261 |
|
|
|
40,406 |
|
Netherlands |
|
|
21,172 |
|
|
|
22,022 |
|
|
|
19,501 |
|
|
|
|
25,687 |
|
|
|
48,501 |
|
|
|
61,021 |
|
Geographic segmentation of the Company’s net income (loss) for the year ended April 30, 2025, 2024 and 2023 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years ended
April 30, |
|
Net Income (Loss) by Region
(in thousands) |
|
2025
$ |
|
|
2024
$ |
|
|
2023
$ |
|
North America - Corporate |
|
|
(8,142 |
) |
|
|
(7,846 |
) |
|
|
(8,422 |
) |
North America |
|
|
699 |
|
|
|
(449 |
) |
|
|
(12,601 |
) |
Belgium |
|
|
(23,908 |
) |
|
|
(19,009 |
) |
|
|
(7,024 |
) |
Netherlands |
|
|
1,117 |
|
|
|
1,189 |
|
|
|
1,487 |
|
|
|
|
(30,234 |
) |
|
|
(26,115 |
) |
|
|
(26,560 |
) |
Geographic segmentation of the interest and accretion, and amortization and depreciation for the year ended April 30, 2025, 2024 and 2023 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years ended
April 30, |
|
Interest and accretion
(in thousands) |
|
2025
$ |
|
|
2024
$ |
|
|
2023
$ |
|
North America - Corporate |
|
|
39 |
|
|
|
4 |
|
|
|
39 |
|
North America |
|
|
223 |
|
|
|
231 |
|
|
|
19 |
|
Belgium |
|
|
— |
|
|
|
— |
|
|
|
20 |
|
Netherlands |
|
|
697 |
|
|
|
619 |
|
|
|
318 |
|
|
|
|
959 |
|
|
|
854 |
|
|
|
396 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years ended
April 30, |
|
Amortization and depreciation
(in thousands) |
|
2025
$ |
|
|
2024
$ |
|
|
2023
$ |
|
North America - Corporate |
|
|
5 |
|
|
|
11 |
|
|
|
14 |
|
North America |
|
|
672 |
|
|
|
687 |
|
|
|
720 |
|
Belgium |
|
|
1,612 |
|
|
|
2,422 |
|
|
|
2,543 |
|
Netherlands |
|
|
2,830 |
|
|
|
2,615 |
|
|
|
3,408 |
|
|
|
|
5,119 |
|
|
|
5,735 |
|
|
|
6,685 |
|
|